Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Koexistenz von Depression, Angst, traumatischem Stress und körperlicher Krankheit – allgemeine Positionen Kapitel lesen Erstes Kapitel lesen

2022 | OriginalPaper | Buchkapitel

7. Erkrankungen von Leber und Pankreas

verfasst von : Hans-Peter Kapfhammer

Erschienen in: Depression, Angst, traumatischer Stress und internistische Erkrankungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

In einer Perspektive der psychischen und somatischen Komorbidität werden folgende Krankheiten der Leber und der Bauchspeicheldrüse betrachtet: Virus-Hepatitis C, alkoholische Fettleberhepatitis, nicht-alkoholische Fettleberhepatitis, Endstadien chronischer Lebererkrankungen mit Zirrhose sowie Pankreaskarzinom. Der Einfluss vorbestehender affektiver und Stress-bezogener Störungen auf die Entwicklung spezifischer hepatischer Erkrankungsrisiken ist vielschichtig zu beurteilen. Patienten mit Virus-Hepatitis C und alkoholischer Fettleberhepatitis akquirieren ihre Erkrankungen häufig in einem psychosozialen Risikokontext, der per se mit erhöhten Raten vorbestehender psychischer, sowohl affektiver als auch Substanz-bezogener Störungen assoziiert ist. Auch bei Personen mit nicht-alkoholischer Fettleberhepatitis ist ein pathologisches Essverhalten häufig ebenfalls auf dem Boden affektiver und Stress-bezogener Einflüsse zu untersuchen. Das signifikant erhöhte Niveau von Depression und Angst vor der Diagnose eines Pankreaskarzinoms ist am ehesten als eine zentralnervös vermittelte Prodromalmanifestation eines klinisch noch okkulten kanzerogenen Prozesses zu verstehen. Resultate aus empirischen Studien zur Psychotherapie und Pharmakotherapie koexistenter affektiver und Stress-bezogener Symptome bei den diversen hepatischen Krankheiten werden referiert.
Literatur
Addolorato G, Mirijello A, Leggio L (2013) Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res 37:1601–1608CrossRef
Addolorato G, Mirijello A, Barrio P, Gual A (2016) Treatment of alcohol use disorders in patients with alcoholic liver disease. J Hepatol 65:618–630CrossRef
Adinolfi LE, Nevola R, Lus G et al (2015) Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol 21:2269–2280CrossRef
Adinolfi LE, Nevola R, Rinaldi L et al (2017) Chronic hepatitis C virus infection and depression. Clin Liver Dis 21:517–534CrossRef
Akechi T, Nakano T, Azizuki N et al (2003) Somatic symptoms for diagnosing major depression in cancer patients. Psycosmatics 44:244–248CrossRef
Akizuki N, Shimizu K, Asai M et al (2016) Prevalence and predictive factors of depression and anxiety in patients with pancreatic cancer: a longitudinal study. Jpn J Clin Oncol 46:71–77CrossRef
Allen AM, Therneau TM, Larson JJ et al (2018) Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology 67:1726–1736CrossRef
Al-Omari A, Cowan J, Turner L, Cooper C (2013) Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis. Can J Gastroenterol 27:575–581CrossRef
Aluzaite K, Fraser M, Johnson S et al (2020) Successful use of generic direct acting antiviral medications to treat hepatitis C – a New Zealand-wide study. N Z Med J 133(1525):53–56
Archer M, Niemelä O, Luoto K et al (2019) Status of inflammation and alcohol use in a 6-month follow-up study of patients with major depressive disorder. Alcohol 81:21–26CrossRef
Asnis GM, De La Garza 2nd R (2006) Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 40:322–335
Averill LA, Purohit P, Averill CL et al (2017) Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies. Neurosci Lett 649:147–155CrossRef
Baki JA, Tapper EB (2019) Contemporary epidemiology of cirrhosis. Curr Treat Options Gastroenterol 17:244–253CrossRef
Baranyi A, Meinitzer A, Stepan A et al (2013) A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis C infection. Psychother Psychosom 82:332–340CrossRef
Baranyi A, Meinitzer A, Putz-Bankuti C et al (2014) Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection. Psychosom Med 76:197–207CrossRef
Barnes AF, Yeo TP, Leiby B et al (2018) Pancreatic cancer-associated depression: a case report and review of the literature. Pancreas 47:1065–1077CrossRef
Beesley VL, Wockner LF, O’Rourke P et al (2016) Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study. Support Care Cancer 24:3589–3599CrossRef
Behrendt S, Beesdo-Baum K, Zimmermann P et al (2011) The role of mental disorders in the risk and speed of transition to alcohol use disorders among community youth. Psychol Med 41:1073–1085CrossRef
Bektas DK, Demir S (2016) Anxiety, depression levels and quality of life in patients with gastrointestinal cancer in Turkey. Asian Pac J Cancer Prev 17:723–731CrossRef
Bellos S, Skapinakis P, Rai D et al (2016) Longitudinal association between different levels of alcohol consumption and a new onset of depression and generalized anxiety disorder: results from an international study in primary care. Psychiatry Res 243:30–34CrossRef
Belvederi Murri M, Cecere AC, Masotti M et al (2017) Biopsychosocial predictors of interferon-related depression in patients with hepatitis C. Asian J Psychiatr 26:24–28CrossRef
Benkert O, Hippius H (2021) Kompendium der psychiatrischen Pharmakotherapie, 13. Aufl. Springer, BerlinCrossRef
Berridge KC, Robinson TE (2016) Liking, wanting and the incentive-sensitization theory of addiction. Am Psychol 71:670–679CrossRef
Berzigotti A, Garcia-Tsao G, Bosch J et al (2011) Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 54:555–561CrossRef
Bettison TM, Nahm CB, Gill AJ et al (2018) Understanding the pathophysiology of psychological distress and pancreatic cancer: a systematic review. Pancreas 47:376–381CrossRef
Blanco C, Xu Y, Brady K et al (2013) Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: results from National Epidemiological Survey on Alcohol and Related Conditions. Drug Alcohol Depend 132:630–638CrossRef
Bonaccorso S, Marino V, Biondi M et al (2002) Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 72:237–241CrossRef
Bonner JE, Esserman DA, Golin CE, Evon DM (2015) Self-efficacy and adherence to antiviral treatment for chronic hepatitis C. J Clin Gastroenterol 49:76–83CrossRef
Botwinick IC, Pursell L, Yu G et al (2014) A biological basis for depression in pancreatic cancer. HPB (Oxford) 16:740–743CrossRef
Boyd AD, Riba M (2007) Depression and pancreatic cancer. J Nat Compr Cancer Netw 5:113–116CrossRef
Boyd CA, Benarroch-Gampel J, Sheffield KM et al (2012b) The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma. Surgery 152:403–413CrossRef
Brar G, Tsukamoto H (2019) Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol 54:218–225CrossRef
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424CrossRef
Breitbart W, Rosenfeld B, Tobias K et al (2014) Depression, cytokines, and pancreatic cancer. Psychooncology 23:339–345CrossRef
Brintzenhofe-Szoc KM, Levin TT, Li Y et al (2009) Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics 50:383–391CrossRef
Brown JH, Paraskevas F (1982) Cancer and depression: cancer presenting with depressive illness: an autoimmune disease? Br J Psychiatry 141:227–232
Brüning A, Homann N, Preuss R, Wellhöner P (2018) Leber, Galle, Pankreas. In: Braun J, Müller-Wieland D, Renz-Polster H, Krautzig S (2018) Basislehrbuch Innere Medizin. 6. Aufl. Elsevier, Urban & Fischer, München, 577–671
Cabot RC (1932) A case with the clinical appearance of neurosis but with fatal termination. New Engl J Med 206:635–640CrossRef
Cacoub P, Gragnani L, Comarmond C et al (2014) Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 46(suppl 5):S165–S173CrossRef
Capuron L, Miller AH (2004) Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 56:819–824CrossRef
Capuron L, Miller AH (2011) Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 130:226–238CrossRef
Capuron L, Fornwalt FB, Knight BT et al (2009) Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord 119:181–185CrossRef
Capuron L, Pagnoni G, Drake DF et al (2012) Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry 69:1044–1053CrossRef
Capuron L, Lasselin J, Castanon N (2017) Role of adiposity-driven inflammation in depressive morbidity. Neuropsychopharmacology 42:115–128CrossRef
Cargiulo T (2007) Understanding the health impact of alcohol dependence. Am J Health Syst Pharm 64:S5–S11CrossRef
Carney CP, Jones L, Woolson RF et al (2003) Relationship between depression and pancreatic cancer in the general population. Psychosom Med 65:884–888CrossRef
Carrat F, Fontaine H, Dorival C et al (2019) Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 393(10179):1453–1464CrossRef
Castera L, Constant A, Bernard PH et al (2006) Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases. World J Gastroenterol 12:1545–1550CrossRef
Chen WC, Lai HC, Su WP et al (2015) Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: an open-label study. Psychiatry Investig 12:142–145CrossRef
Chen JY, Ren Y, Yan P et al (2018) Tricyclic antidepressant use and the risk of fibrosis progression in hepatitis C-infected persons: Results from ERCHIVES. J Viral Hepat 25:825–833CrossRef
Cheroutre C, Guerrien A, Rousseau A (2020) Contributing of cognitive-behavioral therapy in the context of bariatric surgery: a review of the literature. Obes Surg 30:3154–3166
Clark KL, Loscalzo M, Trask PC et al (2010) Psychological distress in patients with pancreatic cancer–an understudied group. Psychooncology 19:1313–1320CrossRef
Clausen AN, Francisco AJ, Thelen J et al (2017) PTSD and cognitive symptoms relate to inhibition-related prefrontal activation and functional connectivity. Depress Anxiety 34:427–436CrossRef
Constant A, Castera L, Dantzer R et al (2005) Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 66:1050–1057CrossRef
Conway KP, Swendsen J, Husky MM et al (2016) Association of lifetime mental disorders and subsequent alcohol and illicit drug use: results from the national comorbidity survey-adolescent supplement. J Am Acad Child Adolesc Psychiatry 55:280–288CrossRef
Cox-North P, Doorenbos A, Shannon SE et al (2013) The transition to end-of-life care in end-stage liver disease. J Hosp Palliat Nurs 15:209–215CrossRef
Craciun A, Lackner C, Cortez-Pinto H et al (2020) Nonalcoholic fatty liver disease versus alcohol-related liver disease: is it really so different? Curr Pharm Des 26:1093–1109CrossRef
Crespo I, Rodríguez-Prat A, Monforte-Royo C et al (2020) Health-related quality of life in patients with advanced cancer who express a wish to hasten death: a comparative study. Palliat Med 34:630–638CrossRef
Crone CC, Marcangelo M, Lackamp J et al (2017) Gastrointestinal disorders. In: Ferrando S, Levenson J, Owen JA (Hrsg) Clinical manual psychopharmacology in the medically ill, 2. Aufl. American Psychiatric Publishing, Washington, DC, S 129–193
da Luz FQ, Hay P, Wisniewski L, Cordás T, Sainsbury A (2020) The treatment of binge eating disorder with cognitive behavior therapy and other therapies: An overview and clinical considerations. Obes Rev. https://​doi.​org/​10.​1111/​obr.​13180 [Online ahead of print]
Dai WF, Beca J, Helen Guo H, Isaranawatchai W et al (2020) Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer? Cancer Med 9:215–224CrossRef
Dalgard O, Bjoro K, Hellum K et al (2002) Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or effi cacy of therapy. J Intern Med 251:400–406CrossRef
Dalley JW, Robbins TW (2017) Fractionating impulsivity: neuropsychiatric implications. Nat Rev Neurosci 18:158–171CrossRef
D’Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44:217–231CrossRef
D’Amico G, Pasta L, Morabito A et al (2014) Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 39:1180–1193CrossRef
de Knegt RJ, Bezemer G, Van Gool AR et al (2011) Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 34:1306–1317CrossRef
Debell F, Fear NT, Head M et al (2014) A systematic review of the comorbidity between PTSD and alcohol misuse. Soc Psychiatry Psychiatr Epidemiol 49:1401–1425CrossRef
del Piccolo L, Marinelli V, Mazzi MA et al (2021) Prevalence of depression in a cohort of 400 patients with pancreatic neoplasm attending day hospital for major surgery: role on depression of psychosocial functioning and clinical factors. Psychooncology 30:455–462CrossRef
Dew MA, Rosenberger EM, Myaskovsky L et al (2015) Depression and anxiety as risk factors for morbidity and mortality after organ transplantation: a systematic review and meta-analysis. Transplantation 100:988–1003CrossRef
Diez-Quevedo C, Masnou H, Planas R et al (2011) Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 72:522–528CrossRef
Dose AM, Rhudy LM (2018) Perspectives of newly diagnosed advanced cancer patients receiving dignity therapy during cancer treatment. Support Care Cancer 26:187–195CrossRef
Dwight MM, Kowdley KV, Russo JE et al (2000) Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 49:311–317CrossRef
Dworkin ER, Bergman HE, Walton TO et al (2018) Co-occurring post-traumatic stress disorder and alcohol use disorder in U.S. military and veteran populations. Alcohol Res 39:161–169
Edwin D, Flynn L, Klein A, Thuluvath PJ (1999) Cognitive impairment in alcoholic and nonalcoholic cirrhotic patients. Hepatology 30:1363–1367CrossRef
Egmond E, Mariño Z, Navines R et al (2020) Incidence of depression in patients with hepatitis C treated with direct-acting antivirals. Braz J Psychiatry 42:72–76CrossRef
Ehret M, Sobieraj DM (2014) Prevention of interferon-alpha-associated depression with antidepressant medications in patients with hepatitis C virus: a systematic review and meta-analysis. Int J Clin Pract 68:255–261CrossRef
Elberg Dengsø K, Wreford Andersen E, Thomsen T et al (2020) Increased psychological symptom burden in patients with pancreatic cancer: a population-based cohort study. Pancreatology 20:511–521CrossRef
El-Kamary SS, Jhaveri R, Shardell MD (2011) All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. Clin Infect Dis 53:150–157CrossRef
Elman I, Borsook D (2019) The failing cascade: comorbid posttraumatic stress- and opioid use disorders. Neurosci Biobehav Rev 103:374–383CrossRef
Elwing JE, Lustman PJ, Wang HL, Clouse RE (2006) Depression, anxiety, and nonalcoholic steatohepatitis. Psychosom Med 68:563–569CrossRef
Enman NM, Zhang Y, Unterwald EM (2014) Connecting the pathology of posttraumatic stress and substance use disorders: monoamines and neuropeptides. Pharmacol Biochem Behav 117:61–69CrossRef
Enoch MA, Hodgkinson CA, Yuan Q et al (2010) The influence of GABRA2, childhood trauma, and their interaction on alcohol, heroin, and cocaine dependence. Biol Psychiatry 67:20–27CrossRef
Erim Y, Sefik Tagay S, Mingo Beckmann M et al (2010) Depression and protective factors of mental health in people with hepatitis C: a questionnaire survey. Int J Nurs Stud 47:342–349CrossRef
European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: management of alcohol-related liver disease. J Hepatol 69:154–181CrossRef
The European Union HCV Collaborators (2017) Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2:325–333
Evon DM, Simpson K, Kixmiller S et al (2011) A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol 106:1777–1786CrossRef
Evon DM, Golin CE, Fried MW, Keefe FJ (2013) Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol 81:361–374CrossRef
Evon DM, Golin CE, Ruffin R, Fried MW (2017) Development and pilot-testing of a cognitive behavioral coping skills group intervention for patients with chronic hepatitis C. Contemp Clin Trials Commun 6:85–96CrossRef
Evon DM, Stewart PW, Amador J et al (2018b) A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: results from a large US multi-center observational study. PLoS ONE 13:e0196908. https://​doi.​org/​10.​1371/​journal.​pone.​0196908CrossRef
Ewusi-Mensah I, Saunders JB, Wodak AD et al (1983) Psychiatric morbidity in patients with alcoholic liver disease. Br Med J (Clin Res Ed) 287(6403):1417–1419CrossRef
Ewusi-Mensah I, Saunders JB, Williams R (1984) The clinical nature and detection of psychiatric disorders in patients with alcoholic liver disease. Alcohol Alcohol 19:297–302
Fábregas BC, de Ávila RE, Faria MN et al (2013) Health related quality of life among patients with chronic hepatitis C: a cross-sectional study of sociodemographic, psychopathological and psychiatric determinants. Braz J Infect Dis 17:633–639CrossRef
Faccioli J, Nardelli S, Gioia S et al (2021) Neurological and psychiatric effects of hepatitis C virus infection. World J Gastroenterol 27:4846–4861CrossRef
Farooq S, Singh SP, Burke D et al (2020) Pharmacological interventions for prevention of depression in high risk conditions: Systematic review and meta-analysis. J Affect Disord 269:58–69CrossRef
Felitti VJ, Anda RF, Nordenberg D et al (2019) Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults: the Adverse Childhood Experiences (ACE) Study. Am J Prev Med 56:774–786CrossRef
Fetzner MG, McMillan KA, Sareen J, Asmundson GJG (2011) What is the association between traumatic life events and alcohol abuse/dependence in people with and without PTSD? Findings from a nationally representative sample. Depress Anxiety 28:632–638CrossRef
Fialho R, Burridge A, Pereira M et al (2016) Norepinephrine-enhancing antidepressant exposure associated with reduced antiviral effect of interferon alpha on hepatitis C. Psychopharmacology 233:1689–1694CrossRef
Flemming JA, Dewit Y, Mah JM et al (2019) Incidence of cirrhosis in young birth cohorts in Canada from 1997 to 2016: a retrospective population-based study. Lancet Gastroenterol Hepatol 4:217–226CrossRef
Fletcher NF, Wilson GK, Murray J et al (2012) Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology 142:634–643CrossRef
Fontana RJ, Hussain KB, Schwartz SM et al (2002) Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 36:401–407CrossRef
Forton DM, Allsop JM, Main J et al (2001) Evidence for a cerebral effect of the hepatitis C virus. Lancet 358:38–39CrossRef
Fras I, Litin EM, Pearson JS (1967) Comparison of psychiatric symptoms in carcinoma of the pancreas with those in some other intra-abdominal neoplasms. Am J Psychiatry 123:1553–1562CrossRef
Galvão-de Almeida A, Guindalini C, Batista-Neves S et al (2010) Can antidepressants prevent interferon-alpha-induced depression? A review of the literature. Gen Hosp Psychiatry 32:401–405CrossRef
Garrison KL, German P, Mogalian E, Mathias A (2018) The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos 46:1212–1225CrossRef
Gayam V, Jegede O, Tiongson B et al (2020) Outcomes of direct-acting antiviral treatment of psychiatric patients with comorbid hepatitis C virus infection. Dig Dis 38:232–239CrossRef
Gerber T, Schomerus H (2000) Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. Drugs 60:1353–1370CrossRef
Godfrey EL, Stribling R, Rana A (2019) Liver transplantation for alcoholic liver disease: an update. Clin Liver Dis 23:127–139CrossRef
Golden J, O’Dwyer AM, Conroy RM (2005) Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 27:431–438CrossRef
Golden J, Conroy RM, O’Dwyer AM et al (2006) Illness-related stigma, mood and adjustment to illness in persons with hepatitis C. Soc Sci Med 63:3188–3198CrossRef
Golden J, Conroy RM, O’Dwyer AM (2007) Reliability and validity of the Hospital Anxiety and Depression Scale and the Beck Depression Inventory (full and fast screen scales) in detecting depression in persons with hepatitis C. J Affect Disord 100:265–269CrossRef
Grant BF, Stinson FS, Dawson DA et al (2004) Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61:807–816CrossRef
Grant BF, Goldstein RB, Saha TD et al (2015) Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiat 72:757–766CrossRef
Green AI, Austin CP (1993) Psychopathology of pancreatic cancer. A psychobiologic probe. Psychosomatics 34:208–221CrossRef
Greenfield SF, Weiss RD, Muenz LR et al (1998) The effect of depression on return to drinking: a prospective study. Arch Gen Psychiatry 55:259–265CrossRef
Greenfield SF, O’ Leary G (2002) Sex differences in substance disorders. In: Lewis-Hall F et al (Hrsg) Psychiatric illness in women. Am Psychiatric Press, Washington DC, Emerging treatments and research, S 467–533
Griffeth BT, Mehra A (2008) Panic as a harbinger of pancreatic cancer. Psychosomatics 49:538–539CrossRef
Grover VP, Pavese N, Koh SB et al (2012) Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat 19:e89-96CrossRef
Guillot CR, Fanning JR, Liang T et al (2015) An α-synuclein gene (SNCA) polymorphism moderates the association of PTSD symptomatology with hazardous alcohol use, but not with aggression-related measures. J Anxiety Disord 30:41–47CrossRef
Gutteling JJ, de Man RA, van der Plas SM et al (2016) Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 23:1629–1635CrossRef
Hagan TL, Fishbein JN, Nipp RD et al (2017) Coping in patients with incurable lung and gastrointestinal cancers: a validation study of the brief COPE. J Pain Symptom Manag 53:131–138CrossRef
Haroon E, Miller AH (2017) Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications. Curr Top Behav Neurosci 31:173–198CrossRef
Haroon E, Woolwine BJ, Chen X et al (2014) IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology 39:1777–1785CrossRef
Haroon E, Miller AH, Sanacora G (2017) Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology 42:193–215CrossRef
Haroon E, Welle JR, Woolwine BJ et al (2020) Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacology 45:998–1007CrossRef
Hartung TJ, Brähler E, Faller H et al (2017) The risk of being depressed is significantly higher in cancer patients than in the general population: prevalence and severity of depressive symptoms across major cancer types. Eur J Cancer 72:46–53CrossRef
Hasin DS, Grant BF (2015) The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. Soc Psychiatry Psychiatr Epidemiol 50:1609–1640CrossRef
Hasin DS, Sarvet AL, Meyers JL et al (2018) Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiat 75:336–346CrossRef
Häuser W, Zimmer C, Schiedermaier P, Grandt D (2004) Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C. Psychosom Med 66:954–958CrossRef
Head M, Goodwin L, Debell F et al (2016) Post-traumatic stress disorder and alcohol misuse: comorbidity in UK military personnel. Soc Psychiatry Psychiatr Epidemiol 51:1171–1180CrossRef
Heinz A, Batra A, Scherbaum N, Gouzoulis-Mayfrank E (2012) Neurobiologie der Abhängigkeit. Kohlhammer, Stuttgart
Hepgul N, Pariante CM, Baraldi S et al (2018) Depression and anxiety in patients receiving interferon-alpha: the role of illness perceptions. J Health Psychol 23:1405–1414CrossRef
Hézode C (2018) Treatment of hepatitis C: results in real life. Liver Int 38(suppl 1):21–27CrossRef
Hobden B, Bryant J, Carey M et al (2018) Finding the optimal treatment model: A systematic review of treatment for co-occurring alcohol misuse and depression. Aust N Z J Psychiatry 52:737–750CrossRef
Holland JC, Korzun AH, Tross S et al (1986) Comparative psychological disturbance in patients with pancreatic and gastric cancer. Am J Psychiatry 143:982–986CrossRef
Hotho DM, Bezemer G, Hansen BE et al (2014) Effects of escitalopram prophylaxis during antiviral treatment for chronic hepatitis C in patients with a history of intravenous drug use and depression. J Clin Psychiatry 75:1069–1077CrossRef
Hughes E, Bassi S, Gilbody S, Bland M, Martin F (2016) Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry 3:40–48CrossRef
Hughes K, Bellis MA, Hardcastle KA et al (2017) The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. Lancet Pub Health 2:e356–e366CrossRef
Indolfi G, Giometto S, Serranti D et al (2020) Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection. Aliment Pharmacol Ther 52:1125–1133
Iqbal MN, Levin CJ, Levin FR (2019) Treatment for substance use disorder with co-occurring mental illness. Focus (Am Psychiatr Publ) 17:88–97
Jacobi F, Höfler M, Strehle J et al (2014) Psychische Störungen in der Allgemeinbevölkerung. Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul Psychische Gesundheit (DEGS1-MH). Nervenarzt 85:77–87CrossRef
Jacobsson L, Ottosson JO (1971) Initial mental disorders in carcinoma of pancreas and stomach. Acta Psychiatr Scand 221(suppl):120–127CrossRef
Janda M, Neale RE, Klein K et al (2017) Anxiety, depression and quality of life in people with pancreatic cancer and their carers. Pancreatology 17:321–327CrossRef
Jia L, Jiang SM, Shang YY et al (2010) Investigation of the incidence of pancreatic cancer-related depression and its relationship with the quality of life of patients. Digestion 82:4–9CrossRef
Joffe RT, Rubinow DR, Denicoff KD et al (1986) Depression and carcinoma of the pancreas. Gen Hosp Psychiatry 8:241–245CrossRef
Johnson ME, Fisher DG, Fenaughty A, Theno SA (1998) Hepatitis C virus and depression in drug users. Am J Gastroenterol 93:785–789CrossRef
Juanbeltz R, Jesús Castilla J, Iván Martínez-Baz I et al (2019) Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population. Qual Life Res 28:1477–1484CrossRef
Kalivas PW, Volkow ND (2011) New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry 16:974–986CrossRef
Kapfhammer HP (2004) Alkohol und Depression in der Konsultations-Liaison-Psychiatrie. J Neurol Neurochir Psychiatrie 5:30–36
Kapfhammer HP (2020) Herausforderungen und Ziele in der ganzheitlichen Behandlung von Suchterkrankungen. In: Gesundheitsfonds Steiermark. Sucht – Daten, Fakten, Fachbeiträge, Statements, Hilfsangebote. Land Steiermark, 9–13
Kapfhammer HP (2022) Zur Komorbidität von Posttraumatischer Belastungsstörung und Sucht in biopsychosozialer Perspektive. Neuropsychiatrie 36:1–18CrossRef
Kaplan DE (2020) Hepatitis C virus. Ann Intern Med 173: ITC33–ITC48
Karaivazoglou K, Iconomou G, Triantos C et al (2010) Fatigue and depressive symptoms associated with chronic viral hepatitis patients. health-related quality of life (HRQOL). Ann Hepatol 9:419–427CrossRef
Karliner W (1956) Psychiatric manifestations of cancer of the pancreas. NY Med J 16:2251–2252
Kaufman J, Yang BZ, Douglas-Palumberi H et al (2007) Genetic and environmental predictors of early alcohol use. Biol Psychiatry 61:1228–1234CrossRef
Kelsen DP, Portenoy RK, Thaler HT et al (2019) Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 13:748–755CrossRef
Kenner BJ (2018) Early detection of pancreatic cancer: the role of depression and anxiety as a precursor for disease. Pancreas 47:363–367CrossRef
Kesen O, Kani HT, Yanartaş Ö et al (2019) Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents. Turk J Gastroenterol 30:801–806CrossRef
Kessler RC, Nelson CB, McGonagle KA et al (1996) The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 66:17–31CrossRef
Khalil MA, Shousha HI, El-Nahaas SM et al (2021) Depression in patients with chronic hepatitis-C treated with direct-acting antivirals: A real-world prospective observational study. J Affect Disord 282:126–213CrossRef
Khan A, Tansel A, White DL et al (2016) Efficacy of psychosocial interventions in inducing and maintaining alcohol abstinence in patients with chronic liver disease: a systematic review. J Gastroenterol Hepatol 4:191–202
Klein MB, Lee T, Brouillette MJ et al (2014) Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. HIV Clin Trials 15:161–175CrossRef
Kim D, Yoo ER, Li AA et al (2019a) Depression is associated with non-alcoholic fatty liver disease among adults in the United States. Aliment Pharmacol Ther 50:590–598CrossRef
Kim HS, Yang JD, El-Serag HB, Kanwal F (2019b) Awareness of chronic viral hepatitis in the United States: an update from the National Health and Nutrition Examination Survey. J Viral Hepat 26:596–602CrossRef
Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3:760–773CrossRef
Kovacs D, Kovacs P, Eszlari N (2016) Psychological side effects of immune therapies: symptoms and pathomechanism. Curr Opin Pharmacol 29:97–103CrossRef
Kramer L, Hofer H, Bauer E et al (2005) Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection. AIDS 19(suppl 3):S85-92CrossRef
Kramer DJ, Siegal EM, Frogge SJ, Chadha MS (2019) Perioperative management of the liver transplant recipient. Crit Care Clin 35:95–105CrossRef
Kranzler H, Del Boca FK, Rounsaville BJ (1996) Comorbid psychiatric diagnosis predicts three-year outcomes in alcoholics: a posttreatment natural history study. J Stud Alcohol 57:619–626CrossRef
Kraus MR, Schäfer A, Csef H, Scheurlen M, Faller H (2000) Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 41:377–384CrossRef
Kraus MR, Schäfer A, Csef H, Scheurlen M (2005) Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 11:1769–1774CrossRef
Kraus MR, Schäfer A, Faller H et al (2013) Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 64:708–714CrossRef
Kronsten VT, Tranah TH, Pariante C, Shawcross DL (2022) Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 76:665–680CrossRef
Labenz C, Huber Y, Michel M et al (2020) Nonalcoholic fatty liver disease increases the risk of anxiety and depression. Hepatol Commun 4:1293–1301CrossRef
Latter KA, Wilbur DL (1937) Psychic and neurological manifestation of carcinoma of the pancreas. Proceedings of the Mayo Clinic 12:457–462
Le Strat Y, Le Foll B, Dubertret C (2015) Major depression and suicide attempts in patients with liver disease in the United States. Liver Int 35:1910–1916CrossRef
Lee JW, Park SH (2021) Association between depression and nonalcoholic fatty liver disease: Contributions of insulin resistance and inflammation. J Affect Disord 278:259–263CrossRef
Lee K, Otgonsuren M, Younoszai Z et al (2013) Association of chronic liver disease with depression: a population-based study. Psychosomatics 54:52–59CrossRef
Li M, Kouzmina E, McCusker M et al (2017) Pro- and anti-inflammatory cytokine associations with major depression in cancer patients. Psychooncology 26:2149–2156CrossRef
Loftis JM, Hauser P (2004) The phenomenology and treatment of interferon-induced depression. J Affect Disord 82:175–190CrossRef
Lowry D, Burke T, Galvin Z et al (2016) Is psychosocial and cognitive dysfunction misattributed to the virus in hepatitis C infection? Select psychosocial contributors identified. J Viral Hepat 23:584–595CrossRef
Lu D, Andersson TML, Fall K et al (2016) Clinical diagnosis of mental disorders immediately before and after cancer diagnosis: a nationwide matched cohort Study in Sweden. JAMA Oncol 2:1188–1196CrossRef
Macavei B, Baban A, Dumitrascu DL (2016) Psychological factors associated with NAFLD/NASH: a systematic review. Eur Rev Med Pharmacol Sci 20:5081–5097
Maes M, Ringel K, Kubera M et al (2012) Increased autoimmune activity against 5-HT: a key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. J Affect Disord 136:386–392CrossRef
Mahajan S, Avasthi A, Grover S, Chawla YK (2014) Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection. J Psychosom Res 77:109–115CrossRef
Makrilia N, Indeck B, Syrigos K et al (2009) Depression and pancreatic cancer: a poorly understood link. JOP 10:69–76
Marchesini G, Petta S, Dalle Grave R (2016) Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice. Hepatology 63:2032–2043
Marksteiner J, Bodner T, Gurka P (2002) Alkoholinduizierte kognitive Störung. Wien Med Wochenschr 152:98–101CrossRef
Masters RK, Tilstra AM, Simon DH (2017) Mortality from suicide, chronic liver disease, and drug poisonings among middle-aged U.S. white men and women, 1980–2013. Biodemography Soc Biol 63:31–37CrossRef
McAndrews MP, Farcnik K, Carlen P et al (2005) Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 41:801–808CrossRef
McGinn LK, Van Meter A, Kronish I et al (2019) Feasibility and impact of a guided symptom exposure augmented cognitive behavior therapy protocol to prevent symptoms of pharmacologically induced depression: a pilot study. Cognit Ther Res 43:679–692CrossRef
McMaster CM, Wade T, Basten C et al (2021) Rationale and development of a manualised dietetic intervention for adults undergoing psychological treatment for an eating disorder. Eat Weight Disord 26:1467–1481CrossRef
Mehnert A, Brähler E, Faller H et al (2014) Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 32:3540–3546CrossRef
Mellinger JL, Shedden K, Winder GS et al (2018) The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology 68:872–882CrossRef
Meyer EC, Walser R, Hermann B et al (2018) Acceptance and Commitment Therapy for co-occurring posttraumatic stress disorder and alcohol use disorders in veterans: pilot treatment outcomes. J Trauma Stress 31:781–789CrossRef
Meyerhoff DJ, Mon A, Metzler T, Neylan TC (2014) Cortical γ-aminobutyric acid and glutamate in posttraumatic stress disorder and their relationships to self-reported sleep quality. Sleep 37:893–900CrossRef
Miarons M, Sánchez-Ulayar A, Sempere G et al (2019) New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups. Eur J Hosp Pharm 26:135–139CrossRef
Mikolas LA, Jacques K, Huq M, Krasner C, Mambourg SE (2019) Utilizing clinical pharmacist specialist to manage hepatitis C virus patients on direct-acting antiviral therapy. J Pharm Pract 32:655–663CrossRef
Miller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22–34CrossRef
Miller MW, Lin AP, Wolf EJ, Miller DR (2018) Oxidative stress, inflammation, and neuroprogression in chronic PTSD. Harvard Rev Psychiatry 26:57–69CrossRef
Mohd Hanafiah K, Groeger J, Flaxman AD, et al (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57: 1333–1342
Morasco BJ, Rifai MA, Loftis JM et al (2007) A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 103:83–90CrossRef
Morasco BJ, Loftis JM, Indest DW et al (2010) Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 51:401–408CrossRef
Morasco BJ, Greaves DW, Lovejoy TI et al (2016) Development and preliminary evaluation of an integrated cognitive-behavior treatment for chronic pain and substance use disorder in patients with the hepatitis C virus. Pain Med 17:2280–2290CrossRef
Mullish BH, Kabir MS, Thursz MR, Dhar A (2014) Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. Aliment Pharmacol Ther 40:880–892CrossRef
Murthy P, Mahadevan J, Chand PK (2019) Treatment of substance use disorders with co-occurring severe mental health disorders. Curr Opin Psychiatry 32:293–299CrossRef
Mutschler J, Soyka M (2019) Psychosoziale und Psychotherapeutische Behandlungen. In: Soyka M, Batra A, Heinz A, Moggi F, Walter M (Hrsg) Suchtmedizin. Elsevier, München, S 106–112
Naik AD, Arney J, Clark JA et al (2020) Integrated model for patient-centered advanced liver disease care. Clin Gastroenterol Hepatol 18:1015–1024CrossRef
Navinés R, Castellví P, Moreno-España J et al (2012) Depressive and anxiety disorders in chronic hepatitis C patients: reliability and validity of the Patient Health Questionnaire. J Affect Disord 138:343–351CrossRef
Nawijn L, van Zuiden M, Koch SB, et al. (2016) Intranasal oxytocin enhances neural processing of monetary reward and loss in post-traumatic stress disorder and traumatized controls. Psychoneuroendocrinology 66:228–237
Negro F, Forton D, Craxì A et al (2015) Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology 149:1345–1360CrossRef
Nelligan JA, Loftis JM, Matthews AM et al (2008) Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review. J Clin Psychiatry 69:810–816CrossRef
Neuman MG, French SW, Zakhari S et al (2017) Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol 102:162–180CrossRef
Noon S, D’Annibale D, Schwimmer M et al (2021) Incidence of depression and anxiety in a cohort of adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 72:579–583CrossRef
Norris FH, Slone LB (2014) Epidemiology of trauma and PTSD. In: Friedman MJ, Keane TM, Resick TA (Hrsg) Handbook of PTSD. Practice and science, 2 nd ed. Guilford Press, New York, S 100–120
O’Carroll R (2013) Psychological aspects of liver disease and its treatment. Health Psychol Rev 7:111–128CrossRef
O’Shea RS, Dasarathy S, McCullough AJ (2010) Alcoholic liver disease. Hepatology 51:307–328CrossRef
Okuyama T, Akechi T, Mackenzie L, Furukawa TA (2017) Psychotherapy for depression among advanced, incurable cancer patients: a systematic review and meta-analysis. Cancer Treat Rev 56:16–27CrossRef
Olson SH, Xu Y, Herzog K et al (2016) Weight loss, diabetes, fatigue, and depression preceding pancreatic cancer. Pancreas 45:986–989CrossRef
Owen JA, Crouse EL, Kirkwood CK, Levenson JL (2019) Psychopharmacology. In: Levenson JL (Hrsg) The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liaison Psychiatry, 3. Aufl. American Psychiatric Association Publishing, Washington, DC, S 1181–1260
Parikh ND, Marrero WJ, Wang J et al (2019) Projected increase in obesity and non-alcoholic-steatohepatitis–related liver transplantation waitlist additions in the United States. Hepatology 70:487–495CrossRef
Parker R (2019) Editorial: depression in NAFLD—worth looking for. Aliment Pharmacol Ther 50:830–831CrossRef
Parker R, Kim SJ, Gao B (2018) Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations. Nat Rev Gastroenterol Hepatol 15:50–59CrossRef
Passik SD (1996) Supportive care of the patient with pancreatic cancer: role of the psycho-oncologist. Oncology (Williston Park) 10(9 suppl):33–34
Passik SD, Breitbart WS (1996) Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Cancer 78(3 suppl):615–626
Passik SD, Roth AJ (1999) Anxiety symptoms and panic attacks preceding pancreatic cancer diagnosis. Psychooncology 8:268–272CrossRef
Patel AV, Wade JB, Thacker LR et al (2015) Cognitive reserve is a determinant of health-related quality of life in patients with cirrhosis, independent of covert hepatic encephalopathy and model for end-stage liver disease score. Clin Gastroenterol Hepatol 13:987–991CrossRef
Pawlowski T, Malyszczak K, Inglot M et al (2018) Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment. Psychoneuroendocrinology 97:1–7CrossRef
Pecoraro V, Banzi R, Cariani E et al (2019) New direct-acting antivirals for the treatment of patients with hepatitis C virus infection: a systematic review of randomized controlled trials. J Clin Exp Hepatol 9:522–538CrossRef
Peery AF, Crockett SD, Barritt AS, et al. (2015)Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 2015 149:1731–1741.e3
Pedrelli P, Borsari B, Merrill JE et al (2020) Evaluating the combination of a Brief Motivational Intervention plus Cognitive Behavioral Therapy for Depression and heavy episodic drinking in college students. Psychol Addict Behav 34:308–331CrossRef
Peery AF, Crockett SD, Murphy CC et al (2018) Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 156:254–272CrossRef
Pegum N, Connor JP, Feeney GF, Young RM (2011) Neuropsychological functioning in patients with alcohol-related liver disease before and after liver transplantation. Transplantation 92:1371–1377CrossRef
Peng JK, Hepgul N, Higginson IJ, Gao W (2019) Symptom prevalence and quality of life of patients with end-stage liver disease: a systematic review and meta-analysis. Palliat Med 33:24–36CrossRef
Pennington DL, Abé C, Batki SL, Meyerhoff DJ (2014) A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. Psychiatry Res 224:281–287CrossRef
Penninx BWJH, Lange SMM (2018) Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci 20:63–73CrossRef
Perez J, Beale E, Overholser J et al (2022) Depression and alcohol use disorders as precursors to death by suicide. Death Stud 46:619–627CrossRef
Perkonigg A, Kessler RC, Storz S, Wittchen HU (2000) Traumatic events and post-traumatic stress disorder in the community: prevalence, risk factors and comorbidity. Acta Psychiatr Scand 101:46–59CrossRef
Pimpin L, Cortez-Pinto H, Negro F et al (2018) Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J Hepatol 69:718–735CrossRef
Polis S, Fernandez R (2015) Impact of physical and psychological factors on health-related quality of life in adult patients with liver cirrhosis: a systematic review protocol. JBI Database System Rev Implement Rep 13:39–51CrossRef
Raimo EB, Schuckit MA (1998) Alcohol dependence and mood disorders. Addict Behav 23:933–346CrossRef
Raison CL, Borisov AS, Broadwell SD et al (2005) Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 66:41–48CrossRef
Raison CL, Woolwine BJ, Demetrashvili MF et al (2007) Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 25:1163–1174CrossRef
Raison CL, Miller AH (2011) Is depression an inflammatory disorder? Curr Psychiatry Rep 13:467–475
Rankin J, Matthews L, Cobley S et al (2016) Psychological consequences of childhood obesity: psychiatric comorbidity and prevention. Adolesc Health Med Ther 7:125–146
Rawla P, Sunkara T, Gaduputi V (2019) Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 10:10–27CrossRef
Reichenberg A, Gorman JM, Dieterich DT (2005) Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72-week prospective study. AIDS 19(suppl 3):S174-178CrossRef
Rickles NK (1945) Functional symptoms as first evidence of pancreatic disease. J Nerv Mental Dis 101:566–571CrossRef
Roncero C, Villegas JL, Martínez-Rebollar M, Buti M (2018) The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Rev Clin Pharmacol 11:999–1030CrossRef
Rose CF, Amodio P, Bajaj JS et al (2020) Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol 73:1526–1547CrossRef
Rosso IM, Weiner MR, Crowley DJ et al (2014) Insula and anterior cingulate GABA levels in posttraumatic stress disorder: preliminary findings using magnetic resonance spectroscopy. Depress Anxiety 31:115–123CrossRef
Rothenhäusler HB, Scherr M, Putz-Bankuti C et al (2009) Der Zusammenhang zwischen emotionalen Befindlichkeitsstörungen, kognitiver Leistungsfähigkeit und gesundheitsbezogener Lebensqualität bei mit dem Hepatitis-C-Virus infizierten Patienten vor einer antiviralen Therapie. Fortschr Neurol Psychiatr 77:457–463CrossRef
Rounsaville BJ, Dolinsky ZS, Babor TF, Meyer RE (1987) Psychopathology as predictor of treatment outcome in alcoholics. Arch Gen Psychiatry 44:505–513CrossRef
Rowan PJ, Bhulani N (2015) Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments. World J Hepatol 7:2209–2213CrossRef
Rowe IA (2017) Lessons from epidemiology: the burden of liver disease. Dig Dis 35:304–309CrossRef
Russ TC, Kivimäki M, Morling JR et al (2015) Association between psychological distress and liver disease mortality: a meta-analysis of individual study participants. Gastroenterology 148:958-966.e4CrossRef
Ryu JS, Choi SW, Yun SS et al (2018) Preliminary findings on the effectiveness of meaning-centered psychotherapy in patients with pancreatobiliary cancer. Yonsei Med J 59:1107–1114CrossRef
Samokhvalov AV, Awan S, George TP et al (2017) Integrated care pathway for co-occurring major depressive and alcohol use disorders: outcomes of the first two years. Am J Addict 26:602–609CrossRef
Sarkar S, Kemper J, Sarkar R et al (2021) Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression. J Affect Disord 292:766–772CrossRef
Sarkar S, Schäfer M (2014) Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis. Psychosomatics 55:221–234CrossRef
Savage C, Butcher W, Noble D (1952) Psychiatric manifestations in pancreatic disease. J Clin Psychopathol 13:9–16
Scafato E, Caputo F, Patussi V et al (2020) The undertreatment of alcohol-related liver diseases among people with alcohol use disorder. Eur Rev Med Pharmacol Sci 24:974–982
Schäfer M, Schwaiger M, Garkisch AS et al (2005) Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 42:793–798CrossRef
Schäfer A, Wittchen HU, Seufert J, Kraus MR (2007) Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C – a critical review. Int J Methods Psychiatr Res 16(1):86–201
Schäfer A, Wittchen HU, Backmund M et al (2009) Psychopathological changes and quality of life in hepatitis C virus-infected, opioid-dependent patients during maintenance therapy. Addiction 104:630–640CrossRef
Schäfer M, Capuron L, Friebe A et al (2012a) Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 57:1379–1390CrossRef
Schäfer M, Sarkar R, Knop V et al (2012b) Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 157:94–103CrossRef
Shakin EJ, Holland J (1988) Depression and pancreatic cancer. J Pain Symptom Manage 3:194–188
Schlatter C, Egger SS, Tchambaz L, Krähenb€uhl S (2009) Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for does adaptation. Drug Saf 32:561–578
Schmidt F, Janssen G, Martin G et al (2009) Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Aliment Pharmacol Ther 30:1049–1059CrossRef
Schneider U, Altmann A, Baumann M et al (2001) Comorbid anxiety and affective disorder in alcohol-dependent patients seeking treatment: the first Multicentre Study in Germany. Alcohol Alcohol 36:219–223CrossRef
Schuckit MA, Tipp JE, Bergman M et al (1997) Comparison of induced and independent major depressive disorders in 2,945 alcoholics. Am J Psychiatry 154:948–957CrossRef
Schwandt HJ (2002) Schulung bei Leber- und Pankreaserkrankungen: Gesprächsgruppe: „Chronische Lebererkrankungen“ (CL) / „Chronische Pankreaserkrankungen“ (CP). Z Gastroenterol 40(suppl 1):S22–S26CrossRef
Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ (2012) Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 13:465–477CrossRef
Sebti J, Desseigne F, Saltel P (2015) Prodromal depression in pancreatic cancer: retrospective evaluation on ten patients. Palliat Support Care 13:801–807CrossRef
Sechi G, Serra A (2007) Wernicke’s encephalopathy: New clinical settings and recent advances in diagnosis and management. Lancet Neurol 6:442–455CrossRef
Seitz HK, Müller S (2018) Nicht alkoholische (NAFLE) und alkoholische Lebererkrankung (ALE). CME 15:45–57CrossRef
Seitz HK, Stickel F (2007) Alcoholic liver disease in the elderly. Clin Geriatr Med 23:905–921CrossRef
Seoud T, Aslam Syed A, Neil Carleton N et al (2020) Depression before and after a diagnosis of pancreatic cancer: results from a national, population-based study. Pancreas 49:1117–1122CrossRef
Serper M, Evon DM, Amador J et al (2021) Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: results from the PROP UP Study. Liver Int 41:692–704CrossRef
Sheibani-Rad S, Velanovich V (2006) Effects of depression on the survival of pancreatic adenocarcinoma. Pancreas 32:58–61CrossRef
Sheridan DA, Bridge SH, Crossey MM et al (2014) Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency. Metab Brain Dis 29:625–634CrossRef
Shipley LC, Kodali S, Singal AK (2019) Recent updates on alcoholic hepatitis. Dig Liver Dis 51:761–768CrossRef
Shrestha D, Rathi S, Grover S et al (2020) Factors affecting psychological burden on the informal caregiver of patients with cirrhosis: looking beyond the patient. J Clin Exp Hepatol 10:9–16CrossRef
Smith JD, Fu E, Kobayashi MA (2020) Prevention and management of childhood obesity and ist psychological and health comorbidities. Annu Rev Clin Psychol 16:351–378CrossRef
Smolders EJ, de Kanter CTMM, de Knegt RJ et al (2016) Drug-drug interactions between direct-acting antivirals and psychoactive medications. Clin Pharmacokinet 55:1471–1494CrossRef
Socías ME, Karamouzian M, Parent S, Barletta J et al (2019) Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review. Int J Drug Policy 72:146–159CrossRef
Sockalingam S, Links PS, Abbey SE (2011) Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat 18:153–160CrossRef
Sockalingam S, Leung SE, Wnuk S et al (2020) Psychiatric management of bariatric surgery patients: a review of psychopharmacological and psychological treatments and their impact on postoperative mental health and weight outcomes. Psychosomatics 61:498–507CrossRef
Somers JM, Goldner EM, Waraich P, Hsu L (2006) Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 51:100–113CrossRef
Steel Z, Marnane C, Iranpour C et al (2014) The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol 43:476–493CrossRef
Stewart BJR, Turnbull D, Mikocka-Walus AA et al (2015) An aggravated trajectory of depression and anxiety co-morbid with hepatitis C: a within-groups study of 61 Australian outpatients. Clin Pract Epidemiol Ment Health 11:174–179CrossRef
Stewart KE, Levenson JL (2012) Psychological and psychiatric aspects of treatment of obesity and nonalcoholic fatty liver disease. Clin Liver Dis 16:615–629CrossRef
Su KP, Lai HC, Yang HT et al (2014) Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry 76:559–566CrossRef
Su KP, Lai HC, Peng CY et al (2019) Interferon-alpha-induced depression: Comparisons between early- and late-onset subgroups and with patients with major depressive disorder. Brain Behav Immun 80:512–518CrossRef
Suh J, Ressler KJ (2018) Common biological mechanisms of alcohol use disorder and post-traumatic stress disorder. Alcohol Res 39:131–145
Swain MG, Jones DEJ (2019) Fatigue in chronic liver disease: new insights and therapeutic approaches. Liver Int 39:6–19CrossRef
Tan HK, Yates E, Lilly K, Dhanda AD (2020) Oxidative stress in alcohol-related liver disease. World J Hepatol 12:332–349CrossRef
Tarter RE, Switala JA, Arria A, Plail J, Van Thiel DH (1990) Subclinical hepatic encephalopathy. Comparison before and after orthotopic liver transplantation. Transplantation 50:632–637CrossRef
Taylor MJ, Godlewska B, Near J et al (2014) Effect of interferon-α on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study. Psychol Med 44:789–795CrossRef
Telles-Correia D, Mega I (2015) Candidates for liver transplantation with alcoholic liver disease: psychosocial aspects. World J Gastroenterol 21:11027–11033CrossRef
Tobias K, Rosenfeld B, Pessin H, Breitbart W (2015) Measuring sickness behavior in the context of pancreatic cancer. Med Hypotheses 84:231–237CrossRef
Trigg A, Chan E, Kitchen H et al (2019) Psychometric validation of the hepatitis C symptom and impact questionnaire (HCV-SIQv4) in a diverse sample of adults with chronic hepatitis C virus infection treated with an interferon-free Simeprevir-containing regimen. J Health Econ Outcomes Res 6:1–19CrossRef
Udina M, Castellví P, Moreno-España J et al (2012) Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 73:1128–1238CrossRef
Udina M, Moreno-España J, Navinés R et al (2013) Serotonin and interleukin-6: the role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms. Psychoneuroendocrinology 38:1803–1813CrossRef
Udina M, Hidalgo D, Navinés R et al (2014) Prophylactic antidepressant treatment of interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 75:e1113-1121CrossRef
Vaghi G, Gori B, Strigaro G et al (2020) Direct antivirals and cognitive impairment in hepatitis C: a clinical-neurophysiologic study. J Neurovirol 26:870–879CrossRef
Valentine AD, Meyers CA (2005) Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep 7:391–395CrossRef
van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, et al. (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437–1449
Vehling S, Kissane DW, Lo C et al (2017) The association of demoralization with mental disorders and suicidal ideation in patients with cancer. Cancer 123:3394–3401CrossRef
Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147–1161
Velanovich V (2011) The association of quality-of-life measures with malignancy and survival in patients with pancreatic pathology. Pancreas 40:1063–1069CrossRef
Vujanovic AA, Wardle MC, Smith LJ, Berenz EC (2017) Reward functioning in posttraumatic stress and substance use disorders. Curr Opin Psychol 14:49–55CrossRef
Vujanovic AA, Smith LJ, Green CE et al (2018) Development of a novel, integrated cognitive-behavioral therapy for co-occurring posttraumatic stress and substance use disorders: a pilot randomized clinical trial. Contemp Clin Trials 65:123–129CrossRef
Waldby C, Rosengarten M, Treloar C, Fraser S (2004) Blood and bioidentity: ideas about self, boundaries and risk among blood donors and people living with hepatitis C. Soc Sci Med 59:1461–1471CrossRef
Walter FM, Mills K, Mendonca SC et al (2016) Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study. Lancet Gastroenterol Hepatol 1:298–306CrossRef
Watson C, Tallentire CW, Ramage JK et al (2020) Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World J Gastroenterol 26:3686–3711CrossRef
Weaver T, Madden P, Charles V et al (2003) Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry 183:304–313CrossRef
Weinstein AA, de Avila L, Paik J et al (2018) Cognitive performance in individuals with non-alcoholic fatty liver disease and/or type 2 diabetes mellitus. Psychosomatics 59:567–574CrossRef
Weinstein AA, Kallman Price J, Stepanova M et al (2011) Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics 52:127–132CrossRef
Whale R, Fialho R, Rolt M et al (2015) Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort. J Psychosom Res 79:640–645CrossRef
Whale R, Fialho R, Field AP et al (2019) Factor analyses differentiate clinical phenotypes of idiopathic and interferon-alpha-induced depression. Brain Behav Immun 80:519–524CrossRef
Wilder JM, Evon DM, Proeschold-Bell RJ et al (2021) Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives. J Viral Hepat 28:699–709CrossRef
Wilkinson J, Radkowski M, Eschbacher JM et al (2010) Activation of brain macrophages/microglia cells in hepatitis C infectio. Gut 59:1394–1400CrossRef
Willenbring ML, Olson DH (1999) A randomized trial of integrated outpatient treatment for medically ill alcoholic men. Arch Intern Med 159:1946–1952CrossRef
Wilson MP, Castillo EM, Batey AM et al (2010) Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. Int J Psychiatry Med 40:199–215CrossRef
Wittchen HU, Jacobi F, Rehm J et al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655–679CrossRef
Yanny B, Pham NV, Saleh H, Saab S (2020) Approaches to assessing burden in caregivers of patients with cirrhosis. J Clin Transl Hepatol 8:127–134CrossRef
Yaskin JC (1931) Nervous symptoms as earliest manifestations of carcinoma of the pancreas. JAMA 96:1664–1668CrossRef
Yeoh SW, Holmes ACN, Saling MM et al (2018) Depression, fatigue and neurocognitive deficits in chronic hepatitis C. Hepatol Int 12:294–304CrossRef
Young RMcD, Lawford BR, Noble EP, et al. (2002) Harmful drinking in military veterans with post-traumatic stress disorder: association with the D2 dopamine receptor a1 allele. Alcohol Alcohol 37:451–456CrossRef
Younossi Z, Henry L (2014) The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 46(suppl 5):S186-196CrossRef
Younossi Z, Henry L (2015) Systematic review: patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 41:497–520CrossRef
Younossi Z, Park H, Henry L et al (2016a) Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150:1599–1608CrossRef
Younossi ZM, Koenig AB, Abdelatif D et al (2016b) Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84CrossRef
Younossi ZM, Golabi P, Henry L et al (2019a) A comprehensive review of patient-reported outcomes in patients with chronic liver diseases. J Clin Gastroenterol 53:331–341CrossRef
Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S (2019b) Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation 103:22–27CrossRef
Youssef NA, Abdelmalek MF, Binks M et al (2013) Associations of depression, anxiety, and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int 33:1062–1070CrossRef
Zabora J, BrintzenhofeSzoc K, Curbow B et al (2001) The prevalence of psychological distress by cancer site. Psychooncology 10:19–28CrossRef
Zalai D, Morris Sherman M, Kelly McShane K et al (2015) The importance of fatigue cognitions in chronic hepatitis C infection. J Psychosom Res 78:193–198CrossRef
Zalai D, Carney CE, Sherman M et al (2016) Fatigue in chronic hepatitis C infection: understanding patients’ experience from a cognitive-behavioural perspective. Br J Health Psychol 21:157–172CrossRef
Zampino R, Marrone A, Restivo L et al (2013) Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 5:528–540CrossRef
Zeuzem S (2017) Treatment options in hepatitis C—the current state of the art. Dtsch Arztebl Int 114:11–21
Zibbell JE, Asher AK, Patel RC et al (2018) Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health 108:175–181CrossRef
Zilikis N, Dervenis C (2003) Psychosomatic aspects of pancreatic cancer. Pancreatology 3:273–275CrossRef
Zimmermann P, Wittchen HU, Höfler M et al (2003) Primary anxiety disorders and the development of subsequent alcohol use disorders: a 4-year community study of adolescents and young adults. Psychol Med 33:1211–1222CrossRef
Metadaten
Titel
Erkrankungen von Leber und Pankreas
verfasst von
Hans-Peter Kapfhammer
Copyright-Jahr
2022
Verlag
Springer Berlin Heidelberg
Buch
Depression, Angst, traumatischer Stress und internistische Erkrankungen

Print ISBN: 978-3-662-65872-7

Electronic ISBN: 978-3-662-65873-4

Copyright-Jahr: 2022

DOI
https://doi.org/10.1007/978-3-662-65873-4_7

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Bildnachweise